{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-002587","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.861538+00:00","generated_at":"2026-06-27T19:29:53.203898+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Therapeutics receives FDA IND clearance for BDTX-1535; Phase 1 start in Q1 2022","bullets":["FDA allowed IND application for BDTX-1535 on January 10, 2022.","Phase 1 study of BDTX-1535 to begin in Q1 2022.","Company expects to provide a clinical update in the second half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-002587","json":"https://secwatch.observer/filing/0001104659-22-002587.json","markdown":"https://secwatch.observer/filing/0001104659-22-002587.md","text":"https://secwatch.observer/filing/0001104659-22-002587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922002587/0001104659-22-002587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922002587/tm222372d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:29:53.203898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}